Systole Remedies Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 22-06-2024
- Paid Up Capital ₹ 1.50 Cr
as on 22-06-2024
- Company Age 19 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 11.90 Cr
as on 22-06-2024
- Satisfied Charges ₹ 8.28 Cr
as on 22-06-2024
- Revenue 265.78%
(FY 2023)
- Profit 103.76%
(FY 2023)
- Ebitda 127.07%
(FY 2023)
- Net Worth 8.18%
(FY 2023)
- Total Assets 37.52%
(FY 2023)
About Systole Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹11.90 Cr. The company has closed loans amounting to ₹8.28 Cr, as per Ministry of Corporate Affairs (MCA) records.
Mandeep Kalra, Ravneet Singh, Pavneet Kalra, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24230DL2005PTC191854
- Company No.
191854
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jan 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
North East Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Systole Remedies Private Limited offer?
Systole Remedies Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Third Party Manufacturing, Anti Infective Drugs & Medicines, Antibacterial Drugs, Common Disease Medicines, Skin Lightening Drugs, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Anti Infective Agent, Antibiotic Injection.
Who are the key members and board of directors at Systole Remedies?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mandeep Kalra  | Additional Director | 13-Jul-2021 | Current |
| Ravneet Singh | Additional Director | 29-Jun-2021 | Current |
| Pavneet Kalra | Additional Director | 13-Jul-2021 | Current |
| Harsimran Kalra | Additional Director | 17-Jul-2021 | Current |
| Jitender Kalra | Additional Director | 29-Jun-2021 | Current |
Financial Performance of Systole Remedies.
Systole Remedies Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 265.78% increase. The company also saw a substantial improvement in profitability, with a 103.76% increase in profit. The company's net worth moved up by a moderate rise of 8.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Systole Remedies?
In 2023, Systole Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Janus Biotech India Private LimitedActive 5 years 8 monthsRavneet Singh, Harsimran Kalra and 1 more are mutual person
Burgeon Health Series Private LimitedActive 3 years 16 daysRavneet Singh, Harsimran Kalra and 1 more are mutual person
Flanca Life Sciences Private LimitedActive 2 years 17 daysMandeep Kalra, Ravneet Singh and 3 more are mutual person
- Nyx Pharmaceuticals Private LimitedActive 5 years 5 months
Ravneet Singh, Harsimran Kalra and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 30 Mar 2023 | ₹9.40 Cr | Open |
Hdfc Bank Limited Creation Date: 03 Feb 2022 | ₹2.50 Cr | Open |
Others Creation Date: 29 Sep 2020 | ₹2.75 M | Satisfied |
How Many Employees Work at Systole Remedies?
Systole Remedies has a workforce of 9 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Systole Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Systole Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
